Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Synthetic Lethality and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for STK11/LKB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STK11/LKB1 Active Complex (STK11/STRAD/MO25) High purity (>90%), Sf9 Insect Cell expressed for native phosphorylation. Sequence Verified. |
View STK11 Products |
| Gene Delivery | STK11 Promise-ORF / Lentivirus Full-length wild-type and clinical mutant (e.g., tumor-associated loss-of-function) ORFs for stable cell line generation. |
View STK11 Products |
| Benchmark Ab | Anti-STK11 Recombinant Antibody High-affinity rabbit/mouse chimeric clones optimized for Western Blot and IHC control. |
View STK11 Products |
| Validator | STK11 siRNA Set Target-specific gene knockdown pool for synthetic lethality assay validation. |
View STK11 Products |
| Related Target A | AMPK (PRKAA1/2) Direct downstream substrate of STK11; critical for metabolic reprogramming assays. |
View AMPK Products |
| Related Target B | KRAS Co-mutant partner in NSCLC (KL phenotype); essential for resistance bypass studies. |
View KRAS Products |
| Related Target C | SIK2 Salt-inducible kinase downstream of LKB1; emerging target in ovarian and breast cancers. |
View SIK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Low intrinsic kinase activity of monomeric STK11 | Co-expressed heterotrimeric STK11/STRAD/MO25 active complex with verified theoretical molecular weights. |
| Cellular model generation for loss-of-function studies | High-titer Lentiviral particles expressing WT or specific clinical mutants (e.g., L67R, G221D). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies for endogenous expression profiling. |
| False Positives in Synthetic Lethality Screens | Validated siRNA pools targeting STK11 to confirm drug-induced phenotypic dependency. |
Live STK11/LKB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STK11/LKB1-deficient therapeutics is intensifying, with major players shifting focus from direct kinase restoration to synthetic lethality and metabolic vulnerability targeting. As first-generation immunotherapies show limited efficacy in STK11-mutant non-small cell lung cancer (NSCLC), the next wave of R&D is targeting downstream effectors and co-dependent pathways to overcome drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Synthetic Lethal) | Mirati Therapeutics, Bristol Myers Squibb | STK11-mutant NSCLC, Solid Tumors | Selectivity Assay (Need active STK11/STRAD/MO25 complex vs. AMPK panels) |
| Small Molecule (SIK Inhibitors) | Sastra Oncology, Kezar Life Sciences | Ovarian Cancer, Breast Cancer | Downstream Phosphorylation Assay (Need validated AMPK and SIK2 recombinant proteins) |
| Combination Biologics | Amgen, AstraZeneca | KRAS/STK11 Co-mutant NSCLC | Cell Line Construction (Need Lentivirus for stable STK11-knockout cell lines) |